Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

116.57USD
17 Feb 2017
Change (% chg)

$2.32 (+2.03%)
Prev Close
$114.25
Open
$114.01
Day's High
$116.92
Day's Low
$112.20
Volume
548,470
Avg. Vol
539,163
52-wk High
$132.95
52-wk Low
$77.00

ABMD.O

Chart for ABMD.O

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $5,075.38
Shares Outstanding(Mil.): 43.54
Dividend: --
Yield (%): --

Financials

  ABMD.O Industry Sector
P/E (TTM): 108.63 57.94 29.39
EPS (TTM): 1.07 -- --
ROI: 12.11 7.62 13.06
ROE: 12.64 11.43 14.19

BRIEF-Abiomed Q3 GAAP earnings per share $0.34

* Abiomed announces Q3 FY 2017 revenue of $114.7 million, up 34% over prior year

Jan 26 2017

BRIEF-Abiomed Q3 earnings per share $0.34

* Says increasing lower end of its fiscal year 2017 revenue guidance with new range of $440 million to $445 million

Jan 26 2017

BRIEF-Abiomed announces preliminary q3 preliminary revenue

* Abiomed announces preliminary q3 fy 2017 revenue of $114.7 million, up 34% over prior year

Jan 09 2017

BRIEF-Abiomed Q2 revenue of $103 million, up 35 pct over prior year

* Abiomed announces q2 fy 2017 revenue of $103 million, up 35% over prior year

Oct 27 2016

BRIEF-Abiomed receives FDA ide approval for initiation of door to unloading prospective feasibility study

* Abiomed receives fda ide approval for initiation of door to unloading (dtu) prospective feasibility study

Oct 27 2016

BRIEF-Abiomed receives FDA IDE approval for initiation of DTU prospective feasibility study

* Receives FDA IDE approval for initiation of door to unloading (DTU) prospective feasibility study

Oct 27 2016

BRIEF-Abiomed reports Q2 FY 2017 gaap earnings per share $0.20

* Announces Q2 FY 2017 revenue of $103 million, up 35% over prior year

Oct 27 2016

BRIEF-Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare

* Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare

Sep 27 2016

More From Around the Web

Earnings vs. Estimates